Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts

Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts

Cardiff Oncology is a clinical-stage biotechnology company advancing a PLK1 inhibitor across multiple oncology trials. This plan centers on onvansertib, recent FDA-related disclosure, and the company's documented trial catalysts. The pre-revenue biotech has completed an End-of-Phase 2 meeting with the FDA.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is medium for oncology, with onvansertib most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• Cardiff Oncology is a clinical stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers.
• Onvansertib trials include a Phase 2 study in first-line KRAS/NRAS-mutated metastatic colorectal cancer, a completed Phase 2 study in pancreatic cancer, a Phase 1/2 trial in triple-negative breast cancer, and a Phase 1 trial in recurrent or refractory chronic myelomonocytic leukemia and myelodysplastic syndrome/MPN overlap neoplasms.
• The company disclosed a successful End-of-Phase 2 FDA meeting, a documented regulatory milestone.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Cardiff Oncology reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

Cardiff Oncology's PLK1-focused pipeline

Cardiff Oncology is a clinical stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. The company remains a pre-revenue biotechnology company focused on advancing onvansertib, a selective PLK1 inhibitor, through multiple clinical trials.

A Phase 2 trial (NCT06106308) is studying onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for first-line treatment of metastatic colorectal cancer in adults with KRAS or NRAS mutations. This trial is active but not currently recruiting.

A Phase 2 study (NCT04752696) evaluating onvansertib in combination with nanoliposomal irinotecan, leucovorin, and fluorouracil for second-line treatment of metastatic pancreatic ductal adenocarcinoma has completed. The company also has a Phase 1/2 trial (NCT05383196) studying onvansertib with paclitaxel in triple-negative breast cancer, which is active but not recruiting.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium for oncology. Expect implications for pricing, access, and launch sequencing.

Which trials are recruiting for onvansertib?

Two trials remain in active recruitment. A Phase 1 study (NCT05549661) sponsored by Mayo Clinic is recruiting patients with recurrent or refractory chronic myelomonocytic leukemia and myelodysplastic syndrome/MPN overlap neoplasms to receive onvansertib. An early-phase trial (NCT04005690) is recruiting patients with pancreatic cancer, sponsored by the OHSU Knight Cancer Institute.

IntelligenceStrategic Takeaways▾

Cardiff Oncology is a clinical stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers . Onvansertib trials include a Phase 2 study in first-line KRAS/NRAS-mutated metastatic colorectal cancer , a completed Phase 2 study in pancreatic cancer , a Phase 1/2 trial in triple-negative breast cancer , and a Phase 1 trial in recurrent or refractory chronic myelomonocytic l

FDA End-of-Phase 2 meeting

Cardiff Oncology completed a successful End-of-Phase 2 meeting with the FDA. This regulatory engagement marks a documented milestone in the company's development program.

Frequently Asked Questions